Phase 3 SWOG Cancer Research Network trial led by a City of Hope

LOS ANGELES and PORTLAND, Ore. — A Phase 3 trial has demonstrated that patients with advanced stage (3 or 4) classic Hodgkin lymphoma who underwent initial treatment with nivolumab, a PD-1 checkpoint inhibitor, and AVD chemotherapy (N-AVD) had a significantly lower risk of their cancer getting worse than patients treated…Read More